Abstract
In recent years, the notion that "excessive B12 intake can cause cancer" has circulated online. These views often stem from epidemiological studies where individuals with abnormally high blood vitamin B12 levels are found to have a higher incidence of cancer diagnoses in subsequent years. However, current research indicates that this relationship is primarily a statistical correlation (association) and does not mean that B12 supplementation causes cancer. Most evidence suggests that abnormally elevated B12 is more likely a biomarker for underlying diseases rather than a cause of cancer.
I. Research Evidence: The Link Between High B12 and Cancer Risk
A 2019 study published in "Cancer Epidemiology, Biomarkers & Prevention" analyzed data from over 750,000 adults in the UK primary care database. The study showed that when blood B12 exceeded 600 pmol/L, the cancer diagnosis rate began to rise; if B12 > 1000 pmol/L, the risk of being diagnosed with cancer within one year was approximately 4–5 times higher than that of the general population. The most significant increases in risk were observed for liver cancer, pancreatic cancer, and certain hematological malignancies.
A systematic review published in "Cancer Investigation" in 2024 integrated multiple studies, showing that the hazard ratio for cancer in populations with long-term B12 ≥1000 pg/mL was approximately 1.88–5.9 times. Some studies also observed higher all-cause mortality, but the results were inconsistent. The authors noted that current evidence mostly comes from observational studies and therefore cannot directly prove causality.
II. Clinical Significance of Persistently High B12
Research also found that if B12 consistently tested ≥1000 ng/L in multiple tests, the risk of being diagnosed with solid cancer in subsequent years might increase by approximately 5–6 times. Therefore, clinically, "persistently high B12" is often considered a warning sign requiring further evaluation.
III. Medical Explanation: High B12 as a Warning Indicator
Current clinical research tends to suggest that abnormally elevated B12 is more like a biomarker of disease than a cause of cancer.
When the body experiences tumors, chronic inflammation, or certain organ diseases, B12's metabolism and transport mechanisms may be affected. For example:
• Liver disease: The liver is the main storage organ for B12; when the liver is inflamed or has tumors, it may release large amounts of B12 into the blood.
• Blood or bone marrow diseases: Certain diseases increase B12 binding proteins, leading to elevated blood B12 levels.
• Inflammation or tumors affecting B12 metabolism: Tumors may alter B12's transport or metabolic mechanisms.
Therefore, the more reasonable causal relationship is:
Disease → affects B12 metabolism → elevated blood B12
Rather than: B12 supplementation → causes cancer.
IV. B12 is Essential for the Human Body
Vitamin B12 is a vital essential nutrient for the human body, and chronic deficiency can lead to serious health problems.
• Nervous system protection: B12 is involved in myelin sheath formation. Deficiency can lead to numbness in hands and feet, memory loss, or low mood.
• Red blood cell production: B12 is an important factor in red blood cell production. Deficiency can cause megaloblastic anemia, leading to fatigue, dizziness, and reduced physical strength.
• DNA and cell repair: B12 is involved in DNA synthesis and cell repair, helping to maintain normal cell function.
Therefore, for individuals at risk of deficiency, appropriate B12 supplementation remains a necessary and safe nutritional strategy.
V. B12 Absorption Rate and Reasons for High-Dose Supplementation
When discussing B12 supplementation, people often wonder: why do many B12 supplements contain dosages of 500–1000 micrograms (μg) or even higher? This is related to the body's mechanism for absorbing B12.
Under normal circumstances, B12 in food needs to be released by stomach acid and then bind with intrinsic factor secreted by the stomach before it can be absorbed in the terminal ileum of the small intestine. Through this mechanism, the amount of B12 the body can absorb at one time is quite limited, usually around 1.5–2 micrograms.
When B12 is taken as a supplement, in addition to absorption via intrinsic factor, a small portion is also absorbed into the bloodstream through passive diffusion, but the absorption rate is usually only about 1%.
For example:
2–3 μg → approximately 1.5–2 μg
100 μg → approximately 2–3 μg
1000 μg → approximately 10 μg
Therefore, high-dose B12 is primarily designed to ensure that even with limited absorption, a sufficient effective intake is provided. Clinically, for individuals with poor absorption (such as the elderly, gastrectomy patients, or those with certain gastrointestinal diseases), doctors may also recommend higher doses of oral B12 to increase the actual absorbed amount.
VI. Conclusion
Current research indicates a statistical correlation between high blood B12 and an increased risk of cancer, but there is no evidence that B12 supplementation causes cancer. Abnormally elevated B12 is more likely a biomarker for underlying diseases.
Therefore, the true meaning of "don't take B12 indiscriminately" is not to fear B12, but to remind us to consider whether supplementation is truly necessary, whether the dosage is reasonable, and to monitor blood indicators when needed. Through individualized assessment and appropriate supplementation, both nutritional needs and health safety can be balanced.
References
1. Arendt JFH, Nexo E. Elevated vitamin B12 levels and cancer risk in UK primary care: A THIN database cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2019.
2. Amado-Garzon SB et al. Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review. Cancer Investigation. 2024.
3. Ermens AAM, Vlasveld LT, Lindemans J. Persistent elevation of plasma vitamin B12 is strongly associated with solid cancer. European Journal of Internal Medicine. 2021.
4. Andres E et al. The pathophysiology of elevated vitamin B12 in clinical practice. QJM: An International Journal of Medicine. 2013.
